Home › NDC Lookup › RxCUI directory › RxCUI 2571846

Atogepant 30 MG Oral Tablet [Qulipta] — RxCUI 2571846

RxNorm drug concept · Semantic branded drug
RxCUI 2571846 Semantic branded drug · SBD ● Current RxNorm concept 3 FDA products 7 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2571846
Official nameAtogepant 30 MG Oral Tablet [Qulipta]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asQulipta 30 MG Oral Tablet
FDA products mapped3
Package NDCs mapped7
Reported Medicaid activity (SDUD)190,760 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Atogepant: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It helps prevent migraine in adults. You take it regularly, including for episodic or chronic migraine, rather than using it once a migraine has started.
  • Qulipta is a tablet you take by mouth once a day. You can take it with or without food. Your prescriber will set the right amount for you, so follow their directions.
  • The most common are nausea, constipation, and feeling tired or sleepy. Tell your pharmacist or doctor if they bother you or don't ease up.
  • Get emergency help for trouble breathing, facial swelling, hives, or a serious rash, since these can be allergic reactions. Call your doctor if you notice higher blood pressure or...
📖 Read our full Atogepant guide →

🕸️ Concept Web — How Atogepant 30 MG Oral Tablet [Qulipta] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Atogepant 30 MG Oral Tablet [Qulipta] RxCUI 2571846

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Atogepant 2571813
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Qulipta 2571837
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Atogepant Oral Tablet 2571835
    • Atogepant Oral Product 2571833
    • Atogepant Pill 2571834
    • Atogepant Oral Tablet [Qulipta] 2571841
    • Qulipta Oral Product 2571839
    • Qulipta Pill 2571840
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Atogepant 30 MG Oral Tablet SCD · 2571844
  • Atogepant 30 MG SCDC · 2571843
  • Atogepant Oral Tablet SCDF · 2571835
  • Atogepant Oral Product SCDG · 2571833
  • Atogepant Pill SCDG · 2571834

Brand-Name Concepts

  • Atogepant 30 MG [Qulipta] SBDC · 2571845
  • Atogepant Oral Tablet [Qulipta] SBDF · 2571841
  • Qulipta Oral Product SBDG · 2571839
  • Qulipta Pill SBDG · 2571840
  • Qulipta BN · 2571837

📦 FDA Products & Package NDCs

3 products · 7 package NDCs
7 package NDCs map to RxCUI 2571846 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00074-7094-04 4 TABLET in 1 BOTTLE (0074-7094-04) Qulipta AbbVie Inc. 2021-10-06
00074-7094-30 30 TABLET in 1 BOTTLE (0074-7094-30) Qulipta AbbVie Inc. 2021-09-30
00074-7094-70 4 TABLET in 1 BOTTLE (0074-7094-70) Qulipta AbbVie Inc. 2025-12-17
00074-7095-30 30 TABLET in 1 BOTTLE (0074-7095-30) Qulipta AbbVie Inc. 2021-09-30
00074-7096-04 4 TABLET in 1 BOTTLE (0074-7096-04) Qulipta AbbVie Inc. 2021-10-06
00074-7096-30 30 TABLET in 1 BOTTLE (0074-7096-30) Qulipta AbbVie Inc. 2021-09-30
00074-7096-70 4 TABLET in 1 BOTTLE (0074-7096-70) Qulipta AbbVie Inc. 2026-02-06
Observed labelers: AbbVie Inc. (7) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.